Denali Therapeutics Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Denali Therapeutics Inc. (DNLI) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$107.61 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-26
- Denali Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$107.61M.
- Denali Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$88.53M.
- Denali Therapeutics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$30.49M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$107.61M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$88.53M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$30.49M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |